| 前收市價 | 1.2000 |
| 開市 | 1.2000 |
| 買盤 | 0.2800 |
| 賣出價 | 2.8600 |
| 拍板 | 195.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 1.2000 - 1.2000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 322 |
Motley FoolThe Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
There's probably a big enough pie here for everyone to get a slice.
BenzingaAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
Motley FoolWhere Will Amgen Be in 3 Years?
The Amgen of 2027 could be much be larger than some investors expect.
